ABPI welcomes new Chief Scientific Officer

Amy Schofield 25 January 2018

The Association of the British Pharmaceutical Industry (ABPI) has announced the appointment of Professor Carole Longson MBE as its Chief Scientific Officer.

Prof Longson joins the ABPI from her current role as Executive Director and Board Member at the National Institute for Health and Care Excellence (NICE), and brings significant research, academic and pharmaceutical industry experience to the role, including seven years as a Research Lead at GlaxoSmithKline R&D. 

She will be responsible for leading the Research, Medical and Innovation function at the ABPI with a remit to shape and develop UK pharmaceutical science policy and to ensure that the UK remains at the forefront of innovation in medicines research, development and manufacturing now and into the future. 
Prof Longson was a past member of the Scientific Advisory Committee for Innovative Medicines Initiative (IMI), the leading pan-European public- private partnership which funds health research and innovation. She also holds non-Executive Director and advisory roles in other scientific endeavours in the UK and abroad. 

Throughout her career and role at NICE, she has gained valuable understanding of how the public and private sector must continue to collaborate to meet the shared aims of ensuring medical innovation benefits patients in the UK.

Chief Executive of the ABPI, Mike Thompson, said: "UK life sciences is a complex ecosystem of players and I have no doubt that Carole is the right person to help us better collaborate with our research partners and academia, forge strong links with NHS research colleagues and ensure the focus of our industry is on delivering new and exciting medical science."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.